190 related articles for article (PubMed ID: 27061057)
1. Assessing the clinical severity of type 1 von Willebrand disease patients with a microchip flow-chamber system.
Nogami K; Ogiwara K; Yada K; Shida Y; Takeyama M; Yaoi H; Minami H; Furukawa S; Hosokawa K; Shima M
J Thromb Haemost; 2016 Apr; 14(4):667-74. PubMed ID: 27061057
[TBL] [Abstract][Full Text] [Related]
2. Whole blood ristocetin-induced platelet impedance aggregometry does not reflect clinical severity in patients with type 1 von Willebrand disease.
Nakajima Y; Nogami K; Yada K; Ogiwara K; Furukawa S; Shimonishi N; Shima M
Haemophilia; 2019 May; 25(3):e174-e179. PubMed ID: 30866149
[TBL] [Abstract][Full Text] [Related]
3. A microchip flow-chamber assay screens congenital primary hemostasis disorders.
Nakajima Y; Yada K; Ogiwara K; Furukawa S; Shimonishi N; Shima M; Nogami K
Pediatr Int; 2021 Feb; 63(2):160-167. PubMed ID: 32640065
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive evaluation of haemostatic function in von Willebrand disease patients using a microchip-based flow chamber system.
Ogiwara K; Nogami K; Hosokawa K; Ohnishi T; Matsumoto T; Shima M
Haemophilia; 2015 Jan; 21(1):71-80. PubMed ID: 25545301
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of clinical severity in patients with type 2N von Willebrand disease using microchip-based flow-chamber system.
Nakajima Y; Nogami K; Yada K; Kawamura T; Ogiwara K; Furukawa S; Shimonishi N; Takeyama M; Shima M
Int J Hematol; 2020 Mar; 111(3):369-377. PubMed ID: 31741138
[TBL] [Abstract][Full Text] [Related]
6. Usefulness of the Total Thrombus-Formation Analysis System (T-TAS) in the diagnosis and characterization of von Willebrand disease.
Daidone V; Barbon G; Cattini MG; Pontara E; Romualdi C; Di Pasquale I; Hosokawa K; Casonato A
Haemophilia; 2016 Nov; 22(6):949-956. PubMed ID: 27293213
[TBL] [Abstract][Full Text] [Related]
7. Monitoring of coagulation factor therapy in patients with von Willebrand disease type 3 using a microchip flow chamber system.
Ågren A; Holmström M; Schmidt DE; Hosokawa K; Blombäck M; Hjemdahl P
Thromb Haemost; 2017 Jan; 117(1):75-85. PubMed ID: 27761577
[TBL] [Abstract][Full Text] [Related]
8. Bleeding Symptoms and von Willebrand Factor Levels: 30-Year Experience in a Tertiary Care Center.
Moonla C; Akkawat B; Kittikalayawong Y; Sukperm A; Meesanun M; Uaprasert N; Sosothikul D; Rojnuckarin P
Clin Appl Thromb Hemost; 2019; 25():1076029619866916. PubMed ID: 31359769
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of a microfluidic flow assay to screen for von Willebrand disease and low von Willebrand factor levels.
Lehmann M; Ashworth K; Manco-Johnson M; Di Paola J; Neeves KB; Ng CJ
J Thromb Haemost; 2018 Jan; 16(1):104-115. PubMed ID: 29064615
[TBL] [Abstract][Full Text] [Related]
10. A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1 VWD).
Tosetto A; Rodeghiero F; Castaman G; Goodeve A; Federici AB; Batlle J; Meyer D; Fressinaud E; Mazurier C; Goudemand J; Eikenboom J; Schneppenheim R; Budde U; Ingerslev J; Vorlova Z; Habart D; Holmberg L; Lethagen S; Pasi J; Hill F; Peake I
J Thromb Haemost; 2006 Apr; 4(4):766-73. PubMed ID: 16634745
[TBL] [Abstract][Full Text] [Related]
11. Determinants of bleeding phenotype in adult patients with moderate or severe von Willebrand disease.
de Wee EM; Sanders YV; Mauser-Bunschoten EP; van der Bom JG; Degenaar-Dujardin ME; Eikenboom J; de Goede-Bolder A; Laros-van Gorkom BA; Meijer K; Hamulyák K; Nijziel MR; Fijnvandraat K; Leebeek FW;
Thromb Haemost; 2012 Oct; 108(4):683-92. PubMed ID: 22918553
[TBL] [Abstract][Full Text] [Related]
12. Clinical and laboratory variability in a cohort of patients diagnosed with type 1 VWD in the United States.
Flood VH; Christopherson PA; Gill JC; Friedman KD; Haberichter SL; Bellissimo DB; Udani RA; Dasgupta M; Hoffmann RG; Ragni MV; Shapiro AD; Lusher JM; Lentz SR; Abshire TC; Leissinger C; Hoots WK; Manco-Johnson MJ; Gruppo RA; Boggio LN; Montgomery KT; Goodeve AC; James PD; Lillicrap D; Peake IR; Montgomery RR
Blood; 2016 May; 127(20):2481-8. PubMed ID: 26862110
[TBL] [Abstract][Full Text] [Related]
13. Quantitative impact of using different criteria for the laboratory diagnosis of type 1 von Willebrand disease.
Quiroga T; Goycoolea M; Belmont S; Panes O; Aranda E; Zúñiga P; Pereira J; Mezzano D
J Thromb Haemost; 2014 Aug; 12(8):1238-43. PubMed ID: 24796601
[TBL] [Abstract][Full Text] [Related]
14. CLEC4M and STXBP5 gene variations contribute to von Willebrand factor level variation in von Willebrand disease.
Sanders YV; van der Bom JG; Isaacs A; Cnossen MH; de Maat MP; Laros-van Gorkom BA; Fijnvandraat K; Meijer K; van Duijn CM; Mauser-Bunschoten EP; Eikenboom J; Leebeek FW;
J Thromb Haemost; 2015 Jun; 13(6):956-66. PubMed ID: 25832887
[TBL] [Abstract][Full Text] [Related]
15. A two-centre comparative evaluation of new automated assays for von Willebrand factor ristocetin cofactor activity and antigen.
Stufano F; Lawrie AS; La Marca S; Berbenni C; Baronciani L; Peyvandi F
Haemophilia; 2014 Jan; 20(1):147-53. PubMed ID: 24028703
[TBL] [Abstract][Full Text] [Related]
16. Baseline factor VIII plasma levels and age at first bleeding in patients with severe forms of von Willebrand disease.
Siboni SM; Biguzzi E; Caiani V; Mistretta C; Bucciarelli P; Peyvandi F
Haemophilia; 2016 Jul; 22(4):564-9. PubMed ID: 26843468
[TBL] [Abstract][Full Text] [Related]
17. Quantitative analysis of desmopressin (DDAVP) response in adult patients with type 1 von Willebrand disease.
Guddati AK; Rosovsky RP; Van Cott EM; Kuter DJ
Int J Lab Hematol; 2019 Jun; 41(3):325-330. PubMed ID: 30735311
[TBL] [Abstract][Full Text] [Related]
18. An evaluation of the DDAVP infusion test with PFA-100 and vWF activity assays to distinguish vWD types in children.
Akin M; Karapinar DY; Balkan C; Ay Y; Kavakli K
Clin Appl Thromb Hemost; 2011 Oct; 17(5):441-8. PubMed ID: 20460340
[TBL] [Abstract][Full Text] [Related]
19. Detection of acquired von Willebrand syndrome after ventricular assist device by total thrombus-formation analysis system.
Takashio S; Kaikita K; Nishi M; Morioka M; Higo T; Shiose A; Doman T; Horiuchi H; Fukui T; Tsujita K
ESC Heart Fail; 2020 Oct; 7(5):3235-3239. PubMed ID: 32700467
[TBL] [Abstract][Full Text] [Related]
20. Predictors of von Willebrand disease diagnosis in individuals with borderline von Willebrand factor plasma levels.
Bucciarelli P; Siboni SM; Stufano F; Biguzzi E; Canciani MT; Baronciani L; Pagliari MT; La Marca S; Mistretta C; Rosendaal FR; Peyvandi F
J Thromb Haemost; 2015 Feb; 13(2):228-36. PubMed ID: 25425019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
